For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Congenital Hyperinsulinism - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Congenital Hyperinsulinism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Congenital Hyperinsulinism Understanding
Congenital Hyperinsulinism: Overview
Congenital hyperinsulinism (CHI) is a heterogenous and complex disorder in which the unregulated insulin secretion from pancreatic beta-cells leads to hyperinsulinaemic hypoglycaemia. The severity of hypoglycaemia varies depending on the underlying molecular mechanism and genetic defects. The genetic and molecular causes of CHI include defects in pivotal pathways regulating the secretion of insulin from the beta-cell. The symptoms of CHI include irritability, sleepiness, lethargy, excessive hunger and rapid heart rate. The diagnosis of congenital hyperinsulinism is based on history, laboratory findings, and genetic testing. Prompt diagnosis and establishment of effective treatment are essential to avoid neurologic damage. Medical therapy and surgical intervention are the treatment for CHI.
"Congenital Hyperinsulinism - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided which includes the disease overview and Congenital Hyperinsulinism treatment guidelines. The assessment part of the report embraces, in depth Congenital Hyperinsulinism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Hyperinsulinism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Congenital Hyperinsulinism R&D. The therapies under development are focused on novel approaches to treat/improve Congenital Hyperinsulinism.
Congenital Hyperinsulinism Emerging Drugs Chapters
This segment of the Congenital Hyperinsulinism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Congenital Hyperinsulinism Emerging Drugs
- Dasiglucagon: Zealand Pharma
Dasiglucagon is an analog of human glucagon that is stable in aqueous formulation. The drug is sold under the brand name Zegalogue for the treatment of hypoglycemia. In 2017, the US FDA and the European Commission both granted Orphan Drug designation to dasiglucagon for the treatment of CHI. The drug is in Phase III clinical studies for the treatment of CHI.
Further product details are provided in the report ..
Congenital Hyperinsulinism: Therapeutic Assessment
This segment of the report provides insights about the different Congenital Hyperinsulinism drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Congenital Hyperinsulinism
There are approx. 5+ key companies which are developing the therapies for Congenital Hyperinsulinism. The companies which have their Congenital Hyperinsulinism drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma.
- Phases
DelveInsight's report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Congenital Hyperinsulinism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Congenital Hyperinsulinism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital Hyperinsulinism drugs.
Congenital Hyperinsulinism Report Insights
- Congenital Hyperinsulinism Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Congenital Hyperinsulinism Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Congenital Hyperinsulinism drugs?
- How many Congenital Hyperinsulinism drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Congenital Hyperinsulinism?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Congenital Hyperinsulinism therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Congenital Hyperinsulinism and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Zealand Pharma
- Eiger BioPharmaceuticals
- Crinetics Pharmaceuticals
- AmideBio
- Hanmi Pharmaceutical Company Limited
Key Products
- Dasiglucagon
- Avexitide
- CRN-04777
- AB-G023
- HM15136